虚拟查,分子动力学模拟和EGFR抑制剂作为乳腺癌治疗药物的体外验证

相关实验视频

Updated: May 7, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Swathi R Shetty¹, Sudhan Debnath², Khokan Majumdar³

¹Department of Applied Biology, Council of Scientific & Industrial Research-Indian Institute of Chemical Technology (CSIR-IICT), Uppal Road, Tarnaka, Hyderabad 500007 TS, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.

Bioorganic chemistry

|October 5, 2024

概括

研究人员确定了针对三阴性乳腺癌 (TNBC) 的新型表皮生长因子受体 (EGFR) 抑制剂. 这些化合物在减少癌细胞生长和增强化疗效率方面表现有前途,可能降低副作用.

科学领域:

药用化学医学化学
计算机化药物发现技术
在瘤学瘤学.

背景情况:

皮表皮生长因子受体 (EGFR) 是基底乳腺瘤的一个关键标.
现有的EGFR抑制剂由于剂量限制性细胞毒性而面临限制.
为了有效治疗乳腺癌,需要新的治疗策略.

研究的目的:

确定新的表皮生长因子受体 (EGFR) 抑制剂.
开发和验证用于虚拟查的药理学模型.
评估已识别的化合物对三阴性乳腺癌 (TNBC) 细胞的疗效.

主要方法:

使用已知的EGFR抑制剂生成和验证药类假设.
大型化学数据库 (Phase) 的虚拟选.
ADME过,基于结构的虚拟选,以及分子动力学 (MD) 模拟.
在体外细胞毒性测定和TNBC细胞的机制研究.

主要成果:

一个药理模型 (DHRRR_1) 用于选超过430万种化合物.
确定并验证了五种潜在的EGFR抑制剂 (SN-01至SN-05).
化合物SN-01,SN-03,SN-04和SN-05显示出对TNBC细胞的细胞毒性.
这些抑制剂减少了EGF诱导的增殖,迁移,瘤性和EGFR激活.
在较低度下,SN-04和SN-05增强了多克索鲁比辛的疗效和诱导亡.

结论:

新的EGFR抑制剂 (SN-01至SN-05) 被发现具有强大的抗TNBC活性.
SN-04和SN-05通过减少多克索鲁比剂量和副作用,显示出改善化疗结果的潜力.
这些发现为开发更有效的乳腺癌疗法提供了有希望的途径.

关键词:

细胞毒性细胞毒性对接研究对接研究这是一种EGFR抑制剂.在体外的瘤发生.分子动力学模拟模型法马科福尔的假设.

更多相关视频

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...